Na Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Na Wang has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
Peng Guan
Department of Physiology, School of Pharmacy, Hebei University of Chinese Medicine, Shijiazhuang, Hebei 050091, P.R. China
6 shared publications- En-Sheng Ji
Hebei Technology Innovation Center of TCM Combined Hydrogen Medicine, Hebei University of Chinese Medicine, Shijiazhuang, China
5 shared publications Jian-Xin Wang
Department of Physiology, Hebei University of Chinese Medicine, Shijiazhuang, Hebei 050200, China
4 shared publicationsLu-Yun Qin
Department of Physiology
3 shared publicationsYu Chen
Department of Physiology, Hebei University of Chinese Medicine, Shijiazhuang, Hebei 050200, China
3 shared publicationsLi-Fei Luo
Department of Physiology, School of Basic Medical Sciences, Hebei University of Chinese Medicine, Shijiazhuang, China
2 shared publications
Latest Publications
- Open Access
- 30 April 2024
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 175, 116653
Mechanistic study of Huangqi Guizhi Wuwu decoction amelioration of doxorubicin-induced cardiotoxicity by reducing oxidative stress and inhibiting cellular pyroptosis
- 30 April 2024
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 175, 116653
Open AccessMechanistic study of Huangqi Guizhi Wuwu decoction amelioration of doxorubicin-induced cardiotoxicity by reducing oxidative stress and inhibiting cellular pyroptosis
- Open Access
- 10 July 2023
- Published by Spandidos Publications in Experimental and Therapeutic Medicine
- Vol. 26 (2) , 1-15
Cyclovirobuxine D pretreatment ameliorates septic heart injury through mitigation of ferroptosis
Myocardial dysfunction is a frequent complication in patients with severe sepsis. However, effective drugs for the prevention of myocardial dysfunction and the molecular mechanisms of the disease remain elusive. The present study demonstrated that Cyclovirobuxine D (CVB‑D) could improve cardiac dysfunction in a cecal ligation and puncture (CLP) model in rodents and in a lipopolysaccharide (LPS) model in vitro. Echocardiography and histopathological examination were used to detect changes in cardiac structure and function. Kits were used to detect indicators of cardiac injury, transmission electron microscopy to detect structural changes in mitochondria and reverse transcription‑quantitative PCR to detect prostaglandin‑endoperoxide synthase 2 and hamp expression levels. L‑Glutathione and malondialdehyde levels and superoxide dismutase activity were measured using kits. Cell viability was measured with the Cell Counting Kit‑8. Iron metabolism‑related proteins, inflammatory factor levels and related pathway proteins were detected using western blot analysis. Changes in L‑type calcium currents were detected by membrane clamp, and contractility of cardiomyocytes was measured by Ion Optix. CVB‑D attenuated CLP‑induced cardiac malfunction in septic rats, with changes observed in myocardial pathological structure, creatine kinase isoenzyme (CK‑MB), lactate dehydrogenase (LDH) and cardiac troponin I (cTnI). CVB‑D attenuated sepsis‑induced lipid peroxidation and iron overload. In addition, CVB‑D decreased the expression of CK‑MB, LDH and cTnI, suppressed oxidative stress index levels and reduced the production of reactive oxygen species. CVB‑D decreased LPS‑induced cytoplasmic iron overload by increasing upregulation of iron uptake molecules. Conversely, CVB‑D significantly increased the upregulation of ferroportin 1. CVB‑D pretreatment significantly reduced the levels of hamp mRNA compared with the LPS‑treated group. CVB‑D pretreatment significantly reduced inflammatory factor levels and the ratio of phosphorylated vs. total signal transducer and activator of transcription 3. The expression of SLC7A11 and GPX4 was upregulated in septic cells pretreated with CVB‑D, however treatment with ML385 largely decreased this upregulation. Of note, CVB‑D inhibited the inward flow of calcium ions through the LTCC. In conclusion, these findings suggest that CVB‑D alleviated sepsis‑induced cardiac iron toxicity by alleviating iron metabolism.
- 10 July 2023
- Published by Spandidos Publications in Experimental and Therapeutic Medicine
- Vol. 26 (2) , 1-15
Open AccessCyclovirobuxine D pretreatment ameliorates septic heart injury through mitigation of ferroptosis
Myocardial dysfunction is a frequent complication in patients with severe sepsis. However, effective drugs for the prevention of myocardial dysfunction and the molecular mechanisms of the disease remain elusive. The present study demonstrated that Cyclovirobuxine D (CVB‑D) could improve cardiac dysfunction in a cecal ligation and puncture (CLP) model in rodents and in a lipopolysaccharide (LPS) model in vitro. Echocardiography and histopathological examination were used to detect changes in cardiac structure and function. Kits were used to detect indicators of cardiac injury, transmission electron microscopy to detect structural changes in mitochondria and reverse transcription‑quantitative PCR to detect prostaglandin‑endoperoxide synthase 2 and hamp expression levels. L‑Glutathione and malondialdehyde levels and superoxide dismutase activity were measured using kits. Cell viability was measured with the Cell Counting Kit‑8. Iron metabolism‑related proteins, inflammatory factor levels and related pathway proteins were detected using western blot analysis. Changes in L‑type calcium currents were detected by membrane clamp, and contractility of cardiomyocytes was measured by Ion Optix. CVB‑D attenuated CLP‑induced cardiac malfunction in septic rats, with changes observed in myocardial pathological structure, creatine kinase isoenzyme (CK‑MB), lactate dehydrogenase (LDH) and cardiac troponin I (cTnI). CVB‑D attenuated sepsis‑induced lipid peroxidation and iron overload. In addition, CVB‑D decreased the expression of CK‑MB, LDH and cTnI, suppressed oxidative stress index levels and reduced the production of reactive oxygen species. CVB‑D decreased LPS‑induced cytoplasmic iron overload by increasing upregulation of iron uptake molecules. Conversely, CVB‑D significantly increased the upregulation of ferroportin 1. CVB‑D pretreatment significantly reduced the levels of hamp mRNA compared with the LPS‑treated group. CVB‑D pretreatment significantly reduced inflammatory factor levels and the ratio of phosphorylated vs. total signal transducer and activator of transcription 3. The expression of SLC7A11 and GPX4 was upregulated in septic cells pretreated with CVB‑D, however treatment with ML385 largely decreased this upregulation. Of note, CVB‑D inhibited the inward flow of calcium ions through the LTCC. In conclusion, these findings suggest that CVB‑D alleviated sepsis‑induced cardiac iron toxicity by alleviating iron metabolism.
- Open Access
- 18 March 2022
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 13, 812594
Therapeutic Potential of Astragaloside IV Against Adriamycin-Induced Renal Damage in Rats via Ferroptosis
Adriamycin (ADR) has been utilized to treat cancer for several decades. However, ADR-induced renal injury is one of the most common side effects accompanying ADR therapy. In the present study, we revealed that astragaloside IV (ASIV) was beneficial for renal injury caused by Adriamycin. We demonstrated that ASIV significantly ameliorated kidney injury, improved renal dysfunction, reduced oxidative stress, alleviated iron accumulation, and inhibited the induction of ferroptosis by ADR. ASIV also rescued the intracellular levels of nuclear factor-erythroid-2-related factor 2 (Nrf2) and promoted nuclear translocation of Nrf2. These protective effects of ASIV on renal injury might be attained through the ASIV-induced activation of the Pi3K/Akt signaling pathway. In vitro, the treatment of the HK-2 cells with fer-1 or deferoxamine mesylate obviously improved cell viability during Adriamycin administration. On the other hand, the protective role of ASIV can be abrogated by RSL3 to some extent. Moreover, ASIV lowered the expression of transferrin receptor 1 and divalent metal transporter 1 while enhancing the expression of ferropotin 1 and glutathione peroxidase 4 in ADR administrated cells, the effects of which were akin to those of deferoxamine mesylate. Furthermore, ASIV increased the phosphorylation of Pi3K, Akt, and the expression of Nrf2 and glutathione peroxidase 4 compared to HK-2 cells stimulated by ADR. However, Pi3K inhibitor LY294002 abrogated these activations. In conclusion, ferroptosis may involve in ADR-induced nephrotoxicity, and ASIV might protect nephrocytes against ADR-induced ferroptosis, perhaps via activations of the Pi3K/Akt and Nrf2 signaling pathways.
- 18 March 2022
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 13, 812594
Open AccessTherapeutic Potential of Astragaloside IV Against Adriamycin-Induced Renal Damage in Rats via Ferroptosis
Adriamycin (ADR) has been utilized to treat cancer for several decades. However, ADR-induced renal injury is one of the most common side effects accompanying ADR therapy. In the present study, we revealed that astragaloside IV (ASIV) was beneficial for renal injury caused by Adriamycin. We demonstrated that ASIV significantly ameliorated kidney injury, improved renal dysfunction, reduced oxidative stress, alleviated iron accumulation, and inhibited the induction of ferroptosis by ADR. ASIV also rescued the intracellular levels of nuclear factor-erythroid-2-related factor 2 (Nrf2) and promoted nuclear translocation of Nrf2. These protective effects of ASIV on renal injury might be attained through the ASIV-induced activation of the Pi3K/Akt signaling pathway. In vitro, the treatment of the HK-2 cells with fer-1 or deferoxamine mesylate obviously improved cell viability during Adriamycin administration. On the other hand, the protective role of ASIV can be abrogated by RSL3 to some extent. Moreover, ASIV lowered the expression of transferrin receptor 1 and divalent metal transporter 1 while enhancing the expression of ferropotin 1 and glutathione peroxidase 4 in ADR administrated cells, the effects of which were akin to those of deferoxamine mesylate. Furthermore, ASIV increased the phosphorylation of Pi3K, Akt, and the expression of Nrf2 and glutathione peroxidase 4 compared to HK-2 cells stimulated by ADR. However, Pi3K inhibitor LY294002 abrogated these activations. In conclusion, ferroptosis may involve in ADR-induced nephrotoxicity, and ASIV might protect nephrocytes against ADR-induced ferroptosis, perhaps via activations of the Pi3K/Akt and Nrf2 signaling pathways.
- Open Access
- 24 May 2021
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 12
Astragaloside IV Attenuates the Myocardial Injury Caused by Adriamycin by Inhibiting Autophagy
Astragaloside IV (ASIV) is the main active component of Astragalus, and can ameliorate cardiomyocyte hypertrophy, apoptosis and fibrosis. In this experiment, we studied how ASIV reduces the cardiotoxicity caused by adriamycin and protects the heart. To this end, rats were randomly divided into the control, ADR, ADR + ASIV and ASIV groups (n = 6). Echocardiography was used to observe cardiac function, HE staining was used to observe myocardial injury, TUNEL staining was used to observe myocardial cell apoptosis, and immunofluorescence and Western blotting was used to observe relevant proteins expression. Experiments have shown that adriamycin can damage heart function in rats, and increase the cell apoptosis index, autophagy level and oxidative stress level. Further results showed that ADR can inhibit the PI3K/Akt pathway. ASIV treatment can significantly improve the cardiac function of rats treated with ADR and regulate autophagy, oxidative stress and apoptosis. Our findings indicate that ASIV may reduce the heart damage caused by adriamycin by activating the PI3K/Akt pathway.
- 24 May 2021
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 12
Open AccessAstragaloside IV Attenuates the Myocardial Injury Caused by Adriamycin by Inhibiting Autophagy
Astragaloside IV (ASIV) is the main active component of Astragalus, and can ameliorate cardiomyocyte hypertrophy, apoptosis and fibrosis. In this experiment, we studied how ASIV reduces the cardiotoxicity caused by adriamycin and protects the heart. To this end, rats were randomly divided into the control, ADR, ADR + ASIV and ASIV groups (n = 6). Echocardiography was used to observe cardiac function, HE staining was used to observe myocardial injury, TUNEL staining was used to observe myocardial cell apoptosis, and immunofluorescence and Western blotting was used to observe relevant proteins expression. Experiments have shown that adriamycin can damage heart function in rats, and increase the cell apoptosis index, autophagy level and oxidative stress level. Further results showed that ADR can inhibit the PI3K/Akt pathway. ASIV treatment can significantly improve the cardiac function of rats treated with ADR and regulate autophagy, oxidative stress and apoptosis. Our findings indicate that ASIV may reduce the heart damage caused by adriamycin by activating the PI3K/Akt pathway.
- 3 March 2021
- Published by Springer Nature in Molecular and Cellular Biochemistry
- Vol. 476 (7) , 2603-2611
Astragaloside IV inhibits adriamycin-induced cardiac ferroptosis by enhancing Nrf2 signaling
Astragaloside IV (AsIV), an active ingredient isolated from traditional Chinese medicine astragalus membranaceus, is beneficial to cardiovascular health. This study aimed to characterize the functional role of AsIV against adriamycin (ADR)-induced cardiomyopathy. Here, healthy rats were treated with ADR and/or AsIV for 35 days. We found that AsIV protected the rats against ADR-induced cardiomyopathy characterized by myocardial fibrosis and cardiac dysfunction. Meanwhile, ADR increased type I and III collagens, TGF-β, NOX2, and NOX4 expression and SMAD2/3 activity in the left ventricles of rats, while those effects were countered by AsIV through suppressing oxidative stress. Moreover, ADR was found to promote cardiac ferroptosis, whereas administration of AsIV attenuated the process via activating Nrf2 signaling pathway and the subsequent GPx4 expression increasing. These results suggest that AsIV might play a protective role against ADR-induced myocardial fibrosis, which may partly attribute to its anti-ferroptotic action by enhancing Nrf2 signaling.
- 3 March 2021
- Published by Springer Nature in Molecular and Cellular Biochemistry
- Vol. 476 (7) , 2603-2611
Astragaloside IV inhibits adriamycin-induced cardiac ferroptosis by enhancing Nrf2 signaling
Astragaloside IV (AsIV), an active ingredient isolated from traditional Chinese medicine astragalus membranaceus, is beneficial to cardiovascular health. This study aimed to characterize the functional role of AsIV against adriamycin (ADR)-induced cardiomyopathy. Here, healthy rats were treated with ADR and/or AsIV for 35 days. We found that AsIV protected the rats against ADR-induced cardiomyopathy characterized by myocardial fibrosis and cardiac dysfunction. Meanwhile, ADR increased type I and III collagens, TGF-β, NOX2, and NOX4 expression and SMAD2/3 activity in the left ventricles of rats, while those effects were countered by AsIV through suppressing oxidative stress. Moreover, ADR was found to promote cardiac ferroptosis, whereas administration of AsIV attenuated the process via activating Nrf2 signaling pathway and the subsequent GPx4 expression increasing. These results suggest that AsIV might play a protective role against ADR-induced myocardial fibrosis, which may partly attribute to its anti-ferroptotic action by enhancing Nrf2 signaling.
- 8 May 2018
- Published by Wiley in Journal of Cellular Biochemistry
- Vol. 119 (8) , 6452-6460
Fasudil alleviates pressure overload‐induced heart failure by activating Nrf2‐mediated antioxidant responses
The RhoA/Rho‐kinase cascade plays an important role in many aspects of cardiovascular function. This study aims to investigate the protective effects of fasudil, a Rho‐kinase inhibitor, on pressure overload induced heart failure in rats. Pressure overload induced heart failure was induced in SD rats by banding the abdominal aorta for 8 weeks. The rats were divided into four groups: Sham, TAC, TAC plus low dose of fasudil, and TAC plus high dose of fasudil group. Low dose and high dose fasudil were 5 and 10 mg/kg/day, respectively. Rats in the Sham and TAC groups were treated with vehicle. Fasudil effectively inhibited TAC‐induced heart failure, as evaluated by echocardiography and transmission electron microscopy. Fasudil could significantly promote superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPx) activity and significantly decrease malondialdehyde (MDA) content in a dose‐dependent maner in TAC rats. Consistently, fasudil evoked significant nuclear translocation of Nuclear factor (erythroid‐derived 2)‐like 2 (Nrf2) with increased DNA/promoter binding and transactivation of Nrf2 targets. In addition, fasudil increased the content of iron as well as transferrin receptor 1 (TfR1) in TAC rats. A mild oxidative stress induced by iron may activate the antioxidant enzymes by feedback response. Taken together, these results indicate that the protective effect of fasudil may be due to its strong antioxidative activities which related with the activated Nrf2 and its down‐regulated genes. These findings provide a new treatment concept and support the benefit of fasudil treatment in heart failure.
- 8 May 2018
- Published by Wiley in Journal of Cellular Biochemistry
- Vol. 119 (8) , 6452-6460
Fasudil alleviates pressure overload‐induced heart failure by activating Nrf2‐mediated antioxidant responses
The RhoA/Rho‐kinase cascade plays an important role in many aspects of cardiovascular function. This study aims to investigate the protective effects of fasudil, a Rho‐kinase inhibitor, on pressure overload induced heart failure in rats. Pressure overload induced heart failure was induced in SD rats by banding the abdominal aorta for 8 weeks. The rats were divided into four groups: Sham, TAC, TAC plus low dose of fasudil, and TAC plus high dose of fasudil group. Low dose and high dose fasudil were 5 and 10 mg/kg/day, respectively. Rats in the Sham and TAC groups were treated with vehicle. Fasudil effectively inhibited TAC‐induced heart failure, as evaluated by echocardiography and transmission electron microscopy. Fasudil could significantly promote superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPx) activity and significantly decrease malondialdehyde (MDA) content in a dose‐dependent maner in TAC rats. Consistently, fasudil evoked significant nuclear translocation of Nuclear factor (erythroid‐derived 2)‐like 2 (Nrf2) with increased DNA/promoter binding and transactivation of Nrf2 targets. In addition, fasudil increased the content of iron as well as transferrin receptor 1 (TfR1) in TAC rats. A mild oxidative stress induced by iron may activate the antioxidant enzymes by feedback response. Taken together, these results indicate that the protective effect of fasudil may be due to its strong antioxidative activities which related with the activated Nrf2 and its down‐regulated genes. These findings provide a new treatment concept and support the benefit of fasudil treatment in heart failure.